| Document |
Document Title |
|
WO/2022/157173A1 |
The present invention relates to methods of making a nicotinamide ribofuranoside salt, in particular a crystalline nicotinamide ribofuranoside salt, via salt metathesis comprising subjecting nicotinamide ribofuranoside hydrogen malate or...
|
|
WO/2022/147223A2 |
This invention relates to an oligonucleotide comprising one or more 2'-modified nucleosides, wherein the 2'-position of the nucleoside has a structure of formula (I). The invention also relates to a pharmaceutical composition comprising ...
|
|
WO/2022/143740A1 |
Provided are a compound having both regulatory or agonist effects on adenosine A3 receptor activity, a method for preparing the series of compounds, a pharmaceutical composition of the series of compounds, and the medical use of the seri...
|
|
WO/2022/140365A1 |
Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment ...
|
|
WO/2022/133205A1 |
The present invention relates to efficient synthetic processes useful in the preparation of antiviral nucleosides, particularly uridine 4-oxime 5'-(2-methylpropanoate) {(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-d
ihydropy...
|
|
WO/2022/127914A1 |
The invention concerns compounds of formula (I) which modulate, especially agonize alpha kinase 1 (ALPK1) and are useful for treating a condition, disease or disorder in which a decrease or increase in ALPK1 activity contributes to the p...
|
|
WO/2022/127920A1 |
Provided in the present invention are a preparation method for and an intermediate of a 5'-nucleoside prodrug. Specifically, provided in the present invention is a method for preparing a compound of formula VI. The method comprises the s...
|
|
WO/2022/131350A1 |
The purpose of the present invention is to overcome problems in the acquisition of a DNA aptamer in the conventional methods, including the lack of variety of interactions with target molecules, the increase in the cost for aptamer acqui...
|
|
WO/2022/129930A1 |
The present application relates to alkylpyridinium substituted coumarin dyes of formula (I) and their uses as fluorescent labels. For example, these dyes may be used to label nucleotides for nucleic acid sequencing applications. wherein ...
|
|
WO/2022/123432A1 |
Provided herein are compositions for use in treatment of cancer comprising a therapeutically effective amount of harmine or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of cordycepin. ...
|
|
WO/2022/123501A1 |
The invention provides compounds of the Formula (I) or the Formula (Ia) which are useful intermediates in the synthesis of potential antiviral drugs such as 3'-deoxy-3',4'-didehydro-cytidine triphosphate (ddhCTP).
|
|
WO/2022/125735A1 |
The disclosure provides processes for preparing the compound of formula (VIII) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIII) are also provided.
|
|
WO/2022/124410A1 |
Provided are cytosine-type crosslinked nucleoside amidite crystals represented by a structural formula. In the formula, R2 and R2 are substitution groups and R3 is a protector group.
|
|
WO/2022/125031A1 |
The invention relates to trimethyl chitosan nanoparticles containing magnetic -targeted gemcitabine developed for use in the treatment of lung cancer.
|
|
WO/2022/119784A1 |
5' -O-Phenylacetyluridine effectively delivers both phenylacetate and uridine to a subject. It can be used to treat hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.
|
|
WO/2022/109741A1 |
CD73 (also known as ecto-5´-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune...
|
|
WO/2022/114105A1 |
The present invention addresses the problem of a providing NMN having high purity and a low impurity content. The present invention is a high-purity β-nicotinamide mononucleotide (NMN) which has a purity of 99.0 mass% or higher and in...
|
|
WO/2022/109551A1 |
The present invention relates to compounds and methods useful for inhibiting non-receptor tyrosine-protein kinase Src ("Src"). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present inven...
|
|
WO/2022/109244A1 |
Thymidine analogues, 5-substituted 2'-deoxy-2'-[18F]fluoro-arabinofuranosyluracil derivatives, are promising positron emission tomography (PET) tracers being evaluated for noninvasively imaging cancer cell proliferation and/or reporter g...
|
|
WO/2022/104154A1 |
The invention features a method of treating a disease or disorder in a subject, the method comprising administering a therapeutically effective amount of a 5'-tiRNA to treat the disease or disorder in the subject.
|
|
WO/2022/098757A1 |
Provided are HSD17B13 substrates, reaction products, kits, and methods that include the HSD17B13 substrates or reaction products of the HSD17B13 substrates. Some embodiments include methods of treatment. Some such embodiments include det...
|
|
WO/2022/098371A1 |
This instant invention provides compounds that inhibit viruses of the Coronaviridae family. This invention also comprises compounds that inhibit viral nucleic acid polymerases, particularly SARS-CoV-2 RNA-dependent RNA polymerase (RdRp),...
|
|
WO/2022/089612A1 |
Use of a uridine derivative in preparation of a medicament. The medicament is used for preventing or treating a limb disease associated with administration of a chemotherapy drug in a subject. Further provided is a pharmaceutical combina...
|
|
WO/2022/083686A1 |
A modified nucleoside or nucleotide, the 3'-OH of the modified nucleoside or nucleotide being reversibly blocked; meanwhile, the present invention also relates to a kit comprising the nucleoside or nucleotide, and a sequencing method bas...
|
|
WO/2022/086958A1 |
Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.
|
|
WO/2022/084331A2 |
The present disclosure provides novel piperidine- and guanosine-derived ligands that bind specifically to asialoglycoprotein receptor (ASGPR) and nucleotide analogs conjugated thereto that can be incorporated into oligonucleotides, inclu...
|
|
WO/2022/081739A1 |
Provided are compounds of Formula (I') or (I) below, or pharmaceutically acceptable salts thereof, and methods for their use and production.
|
|
WO/2022/081973A1 |
Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
|
|
WO/2022/074391A1 |
The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: W-X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present inven...
|
|
WO/2022/065413A1 |
The present invention addresses the problem of providing a novel artificial nucleic acid, a method for producing the same, and a use thereof. The problem can be solved by an artificial nucleic acid having a unit derived from a compound r...
|
|
WO/2022/058312A1 |
A method of producing 1,4-dihydronicotinamide riboside (NRH) is disclosed. The method comprises providing nicotinamide riboside chloride (NRCl) in a liquid solution; adding a metal dithionite into the liquid solution under a first temper...
|
|
WO/2022/053576A1 |
The present invention relates to a new class of compounds based on a hexose featuring at least two 6-fluorides. The class is useful as inhibitors of 4,6-dehydratase enzymes. Such inhibitors are suitable for use as a medicament, for examp...
|
|
WO/2022/048680A1 |
Provided is a method for preparing adenosine. The method comprises subjecting adenylic acid to a hydrolysis reaction in a protic solvent under an acidic buffer system. Also provided is a method for purifying adenosine. The method compris...
|
|
WO/2022/043531A1 |
The present disclosure relates to ethylene-bridged nucleic acid (ENA) compounds, which may find use in therapy and/or prophylaxis. These ENA compounds may also find use as building blocks for preparing oligonucleotides, said oligonucleot...
|
|
WO/2022/047182A1 |
The current disclosure provides use of high dose nicotinamide adenine dinucleotide (NAD) precursor regimens for reduction of inflammation in human patients with preexisting inflammation. The NAD precursor can be nicotinamide riboside (NR...
|
|
WO/2022/046910A1 |
Prodrugs of 6-mercaptopurine (6-MP) and methods of their use for treating cancers and autoimmune diseases are disclosed.
|
|
WO/2022/040473A1 |
The present invention provides stereoselective processes of manufacture for the phosphoramidate nucleotide Compound 1 or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/038632A1 |
The present invention discloses novel nigericin derivatives of general formula (I) that exhibit low toxicity and inhibition activity against gram-positive bacteria, gram-negative bacteria, and viruses. The present invention also disclose...
|
|
WO/2022/040301A1 |
Various nucleoside phosphate and phosphonate analogues are provided for treatment of viral infections. Methods of preparing the analogues, pharmaceutical compositions containing the analogues, and methods of using the analogues as antivi...
|
|
WO/2022/035852A1 |
Novel N 4 -substituted decitabine analogs are disclosed that exhibit promising in vitro and in vivo therapeutic activity. These novel compounds were shown to be resistant to deamination via cytidine deaminase (CDA) metabolism and provide...
|
|
WO/2022/033589A1 |
The present invention relates to a new crystal form of β-nicotinamide mononucleotide represented by formula (I) and a preparation method therefor. The method of the present invention does not use toxic and harmful organic solvents such ...
|
|
WO/2022/031150A1 |
The present invention provides a conjugate including: cell-membrane-permeable deoxycytidine activated in a triphosphate form in a cell; and a silyl ether-containing linker of which one end is linked to a hydroxyl group of a drug, wherein...
|
|
WO/2022/022472A1 |
Use of a nicotinamide nucleoside triaryl formate compound and a composition thereof in increasing the level of coenzyme I (NAD) in a human body, improving a health condition or treating a related disease, and a compound of formula (II-1)...
|
|
WO/2022/026533A1 |
Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in ...
|
|
WO/2022/019836A1 |
Disclosed herein include methods and compositions for nucleic acid synthesis using a terminal deoxynucleotidyl transferase with deoxyribonucleotide trisphosphates each comprising a modified base with a photocleavable carbon chain moiety ...
|
|
WO/2022/008025A1 |
Disclosed herein are nucleosides and nucleotides analogs, methods for preparing the same, and methods for treating and/or ameliorating infection caused by a Coronaviridae virus, a Caliciviridae virus, an Orthomyxoviridae virus, a Herpesv...
|
|
WO/2021/195533A9 |
This disclosure relates to the synthesis of novel modified oligonucleotides. The synthesis of novel phosphoramidites are also provided.
|
|
WO/2022/004388A1 |
Disclosed are a bridged nucleoside and a nucleotide using the same. The nucleoside according to the present invention is represented by formula (I). The bridged nucleoside of the present invention is usable as a substitute for a phosphor...
|
|
WO/2022/000087A1 |
It is provided the synthesis of an aptamer-like encoded oligomer (ALEnOmer), method of producing same and method of preparing a library of ALEnOmes. More particularly, the method of preparing ALEnOmer comprises coupling at least one phos...
|
|
WO/2022/006231A1 |
Provided herein are compounds and methods of using these compounds to treat disorders related to DPAGT1 function, including cancer and bacterial infections.
|
